Literature DB >> 6125487

Sulthiame in previously untreated epilepsy.

M P Feely, M O'Callaghan, D O'Driscoll, N Callaghan.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6125487     DOI: 10.1007/bf02940174

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


× No keyword cloud information.
  8 in total

1.  Measurement of anti-epileptic drugs in plasma by gas-liquid chromatography.

Authors:  M O'Callaghan; N Callaghan; M Feely; P F Duggan
Journal:  Ir J Med Sci       Date:  1977-08       Impact factor: 1.568

2.  SULTHIAMINE ("OSPOLOT") IN THE TREATMENT OF TEMPORAL LOBE EPILEPSY.

Authors:  J M SUTHERLAND; D A BOWMAN
Journal:  Med J Aust       Date:  1963-09-28       Impact factor: 7.738

3.  GLC determination of sulthiame in plasma.

Authors:  K J Simons; R H Levy
Journal:  J Pharm Sci       Date:  1972-08       Impact factor: 3.534

4.  Sulthiame (Ospolot) as inhibitor of diphenylhydatoin metabolism.

Authors:  J M Hansen; M Kristensen; L Skovsted
Journal:  Epilepsia       Date:  1968-03       Impact factor: 5.864

5.  Sulthiame: evaluation as an anticonvulsant.

Authors:  J R Green; A S Troupin; L M Halperm; P Friel; P Kanarek
Journal:  Epilepsia       Date:  1974-09       Impact factor: 5.864

6.  Phenobarbitone in previously untreated epilepsy.

Authors:  M Feely; M O'Callagan; B Duggan; N Callaghan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-04       Impact factor: 10.154

7.  One drug for epilepsy.

Authors:  S D Shorvon; D Chadwick; A W Galbraith; E H Reynolds
Journal:  Br Med J       Date:  1978-02-25

8.  The therapeutic range for phenytoin - A reappraisal.

Authors:  M Feeley; B Duggan; M O'Callagan; N Callaghan; J Seldrup
Journal:  Ir J Med Sci       Date:  1979-12       Impact factor: 1.568

  8 in total
  1 in total

1.  The temporal aspects of prognosis in epilepsy.

Authors:  S D Shorvon
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-11       Impact factor: 10.154

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.